|
| Press Releases |
|
 |
|
| Friday, March 27, 2026 |
|
|
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy. more info >> |
|
|
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency |
| Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). more info >> |
|
| Monday, March 23, 2026 |
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 |
| Eisai Co., Ltd. and Biogen Inc. announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI?), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. more info >> |
|
| Thursday, March 19, 2026 |
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide) |
| Eisai Co., Ltd. announced today that the administration of the anticancer agent EZH2 inhibitor "Tazverik(R) Tablets 200 mg" (generic name: tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued. We plan to discontinue sales of this product once we have confirmed that it is no longer being administered to any patients. more info >> |
|
| Tuesday, March 17, 2026 |
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced the establishment of Eisai Global Capability Centre (EGCC) within Eisai Knowledge Centre, India, in Visakhapatnam (Vizag), Andhra Pradesh, India. more info >> |
|
| Thursday, March 12, 2026 |
|
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep" more info >> |
|
|
エーザイ、『Pokemon Sleep』とのコラボレーションで眠りの大切さを広く伝える啓発活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、スマートフォン向けアプリ『Pokémon Sleep』とのコラボレーションを通じて、眠りの大切さを広く伝える啓発活動に取り組むことをお知らせします。 more info >> |
|
| Monday, June 3, 2024 |
|
|
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国 TIME誌が選出する「TIME100 Most Influential Companies of 2024」に選定されたことをお知らせします。 more info >> |
|
|
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を強化 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向け、革新的技術やサービスの発掘とそれを有するベンチャー企業の支援、将来的な提携を目的とし、2019 年に開始したベンチャー投資事業を強化し、継続することを決定しましたのでお知らせします。 more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 7, 2026 11:06 HKT/SGT
|
|
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 6, 2026 23:00: JST
|
|
|
Datavault AI 執行長納撒尼爾·T·布拉德利將於 CONV3RGENCE London 及 AssetRush × Zurich 2026 大會發表關於 RWA 代幣化突破性進展的旗艦主題演講
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Datavault AI 首席执行官内森尼尔·T·布拉德利将在 CONV3RGENCE 伦敦峰会及 AssetRush × 苏黎世 2026 峰会上发表关于 RWA 代币化突破性进展的主题演讲
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Honda、「N-BOX」が2025年度 新車販売台数 第1位を獲得
Apr 6, 2026 16:00: JST
|
|
|
JFEと三菱商事、京浜扇島地区における電力事業とデータセンター事業を一体とした共同事業について基本合意書締結
Apr 6, 2026 15:30: JST
|
|
|
JFE Holdings and Mitsubishi Corporation Sign Second MOU to Advance Integrated Power and Data Center Project in Ohgishima, Keihin District
Apr 6, 2026 14:27 JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00: JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00 HKT/SGT
|
|
|
海通恒信2025年報：協同效應加速釋放 新興賽道引領結構升級
Apr 3, 2026 20:28 HKT/SGT
|
|
|
海通恒信2025年报：协同效应加速释放 新兴赛道引领结构升级
Apr 3, 2026 19:43 HKT/SGT
|
|
|
新希望乳業攜手香港十字牌 借道本土老字號共拓港澳市場
Apr 3, 2026 16:51 HKT/SGT
|
|
|
新希望乳业携手香港十字牌 借道本土老字号共拓港澳市场
Apr 3, 2026 16:44 HKT/SGT
|
|
|
新希望乳業與香港十字牌達成戰略合作：雙方充分發揮資源稟賦 助力港澳乳品行業高質量發展
Apr 3, 2026 16:38 HKT/SGT
|
|
|
新希望乳业与香港十字牌达成战略合作：双方充分发挥资源禀赋 助力港澳乳品行业高质量发展
Apr 3, 2026 16:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
